Loading
Adding the antibody daratumumab to a standard three-drug induction and consolidation around autologous transplant deepened responses and delayed progression in newly diagnosed myeloma, establishing four-drug induction.
Phase 3 trial of 1,085 transplant-eligible patients with newly diagnosed multiple myeloma randomised to bortezomib, thalidomide and dexamethasone with or without daratumumab for induction and consolidation around autologous stem cell transplant.
Stringent complete response after consolidation was 29 percent with daratumumab against 20 percent without, measurable residual disease negativity 64 versus 44 percent, and progression-free survival was improved (hazard ratio 0.47 at the first analysis).
Quadruplet induction with a CD38 antibody became the standard for transplant-eligible patients in Europe. PERSEUS later did the same with the lenalidomide-based backbone used elsewhere.
Shares CASSIOPEIA, Newly diagnosed multiple myeloma, transplant-eligible.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Daratumumab, Bortezomib, Dexamethasone.
Shares Daratumumab, Bortezomib, Dexamethasone.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Bortezomib, Dexamethasone.
Shares Thalidomide, Dexamethasone.
Shares Newly diagnosed multiple myeloma, transplant-eligible, Bortezomib, Dexamethasone.
Shares Daratumumab, Bortezomib, Dexamethasone.
Shares Daratumumab, Bortezomib, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/